Articles From: Aastrom Announces Initiation of Commercial Sales of Bone Marrow by Marrow Donation, LLC to Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI)


ANN ARBOR, Mich., June 24, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) , the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the initiation of commercial sales of bone marrow by Marrow Donation, LLC, the company's wholly owned bone marrow collection center located in San Diego, CA.
Sign-up for Aastrom Announces Initiation of Commercial Sales of Bone Marrow by Marrow Donation, LLC investment picks
ANN ARBOR, Mich., June 15, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) , the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, will hold an investor conference call and slide presentation on Monday, June 16, 2014 beginning at 8:30 AM EDT.
Sign-up for Aastrom Announces Investor Conference Call and Webcast June 16, 2014 at 8:30 AM EDT investment picks
2014/6/16
Manufacturing of MACI in Denmark to be discontinued Sales of MACI in Europe, representing 1% of revenues in 2014, temporarily ceased U.S. action plan implemented to optimize R&D, manufacturing and commercial operations Measures expected to enable company to generate positive cash flow from the U.S. Carticel and Epicel business in 2015 Conference call and slide presentation with Aastrom's senior management today at 8:30 a.m. Eastern Time ANN ARBOR, Mich., June 16, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) , the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced its strategic plan to maximize the profitability and growth potential of the cell therapy and regenerative medicine business that it recently acquired from Sanofi.
Sign-up for Aastrom Announces Strategic Plan for Recently Acquired Cell Therapy and Regenerative Medicine Business investment picks
ANN ARBOR, Mich., June 30, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) , the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will be included in the Russell Microcap ® Index, according to information posted by Russell Investments on June 27, 2014.
Sign-up for Aastrom Biosciences Added to Russell Microcap Index investment picks
ANN ARBOR, Mich., Sept.
Sign-up for Aastrom Biosciences Announces Pricing of Public Offering of Common Stock investment picks
U.S. Commercial Business Generates Positive Contribution ANN ARBOR, Mich., Aug.
Sign-up for Aastrom Biosciences Reports Second Quarter 2014 Financial Results investment picks
ANN ARBOR, Mich., Aug.
Sign-up for Aastrom Biosciences to Host Second Quarter 2014 Earnings Call on August 14, 2014 investment picks
2014/9/8
By Razak Musah Baba LONDON--Associated British Foods PLC (ABF.LN) said Monday it expects its clothing and grocery divisions to deliver strong operating profit, offsetting the effects of lower sugar prices and a strengthening of sterling.
Sign-up for AB Foods Says Performances from Grocery, Primark to Offset Forex Effect investment picks
2014/9/15
By Shayndi Raice and Peter Evans LONDON--Anheuser-Busch InBev NV is talking to banks about financing what could be a roughly GBP75 billion ($122 billion) deal to buy global beer rival SABMiller PLC, according to a person familiar with the matter.
Sign-up for AB InBev seeking finance for SABMiller deal investment picks
2014/7/24
Declares Quarterly Cash Dividend UNION CITY, Calif.
Sign-up for Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 investment picks
2014/7/17
UNION CITY, Calif.
Sign-up for Abaxis To Report First Quarter Fiscal Year 2015 Financial Results Thursday, July 24, 2014 investment picks
UNION CITY, Calif.
Sign-up for Abaxis, Inc. Announces USDA Approval of VetScan Canine Ehrlichia Antibody Test Kit investment picks
2014/8/29
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 investment picks
2014/9/2
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference investment picks
2014/9/5
By John Revill Power and automation company ABB Ltd.
Sign-up for ABB and China's BYD to Develop Storage Systems for Electric Cars investment picks
Swiss-based ABB Ltd.
Sign-up for ABB launches $4 billion share buyback program investment picks
By John Revill ZURICH--ABB Ltd.
Sign-up for ABB Says New High Capacity Cables Will Help Win Orders From Competitors investment picks
Abbott and Fonterra to Form Strategic Alliance for Dairy Farming in China Canada NewsWire First Farm Expected to Produce Milk in First Half of 2017 ABBOTT PARK, Ill.
Sign-up for Abbott and Fonterra to Form Strategic Alliance for Dairy Farming in China investment picks
First Farm Expected to Produce Milk in First Half of 2017 ABBOTT PARK, Ill.
Sign-up for Abbott and Fonterra to Form Strategic Alliance for Dairy Farming in China investment picks
ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend investment picks
Abbott Builds Long-Term Commitment in China Canada NewsWire ABBOTT PARK, Ill., July 10, 2014 /CNW/ - Today's announcement of a proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott (NYSE: ABT) has made in China , deepening its commitment in the country.
Sign-up for Abbott Builds Long-Term Commitment in China investment picks
ABBOTT PARK, Ill., July 10, 2014 /PRNewswire/ -- Today's announcement of a proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott (NYSE: ABT) has made in China , deepening its commitment in the country.
Sign-up for Abbott Builds Long-Term Commitment in China investment picks
ABBOTT PARK, Ill., June 25, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2014 financial results on Wednesday, July 16, 2014 , before the market opens.
Sign-up for Abbott Hosts Conference Call for Second-Quarter Earnings investment picks
- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device used in the heart that functions like a stent but dissolves over time - ABSORB IV will compare Absorb to a best-in-class, metallic drug eluting stent in people with coronary artery disease, the most common type of heart disease - Trial will prospectively measure rates of angina, or chest pain, in the first randomized controlled heart stent trial with angina as a primary endpoint to assess impact of angina on healthcare costs and quality of life ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device investment picks
New Study Shows Most Breastfeeding Moms Do Not Consistently Consume Enough Ideal Levels of These Key Nutrients ABBOTT PARK, Ill., July 24, 2014 /PRNewswire/ -- Nutrition needs are greater when breastfeeding than any other time in a woman's life, including pregnancy, yet new research reveals diet alone may not be enough to meet the high nutritional needs during this important time for mom and baby.[1]  Abbott (NYSE: ABT) , the makers of Similac ® and experts in infant nutrition for nearly 90 years, studied the diets of more than 80 lactating women to assess how their nutritional intake compared to dietary recommendations.
Sign-up for Abbott Introduces New Similac® Breastfeeding Supplement with DHA, Lutein and Vitamin E investment picks
NEW YORK (MarketWatch) -- Abbott Laboratories shares (ABT) climbed more than 2% in premarket trade Wednesday, after the company reported better-than-expected second-quarter profit and sales and raised its outlook for the full year.
Sign-up for Abbott Labs shares climb 2.7% as profit, sales top estimates investment picks
By Anna Prior Abbott Laboratories said it will sell its developed markets branded generics pharmaceuticals business to Mylan Inc. in a $5.3 billion deal that includes the formation of a new publicly traded company.
Sign-up for Abbott Labs to sell part of generics business for $5.3 billion investment picks
- Abbott Achieved Top Industry Scores for Economic and Social Performance - Company Recognized for Sustainability Leadership for 10 Consecutive Years ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI) investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Aastrom Announces Initiation of Commercial Sales of Bone Marrow by Marrow Donation, LLC to Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices